Cigna manages which drugs are covered by health plans and then fills those same prescriptions through its own pharmacies.
What this company is and how it runs — written from structure, not news.
Cigna makes money by sitting on both sides of a prescription at once: its Evernorth arm decides which drugs a health plan will cover and extracts rebates from the drug manufacturer, while its Express Scripts pharmacies then physically fill that same prescription and collect a dispensing margin — two revenue streams from a single transaction. Because Evernorth's formulary decisions steer which pharmacy gets the prescription, the two sides feed each other, but state insurance regulators require Cigna to document every dollar moving between them as though the two sides were unrelated companies, so the administrative burden of proving arm's-length dealing grows every time Cigna adds a new employer client or enters a new state. Employers who want to leave face a 12-to-18-month unwinding process, and specialty pharmacy patients on expensive biologics cannot simply transfer to a new network — their physicians must restart prior authorization from scratch, which keeps most patients in place long after a client has decided to move. The whole structure depends on the PBM and the pharmacy staying inside the same corporate roof: if regulators force Cigna to sell one or the other, the formulary-to-dispensing link breaks and what remains is an ordinary PBM or an ordinary pharmacy, neither of which captures both streams.
How does this company make money?
Cigna collects premiums from employers and individuals for medical coverage. Through Evernorth, it charges health plans administrative fees for managing their drug formularies and receives rebate payments from pharmaceutical manufacturers in exchange for favorable formulary placement. Through Express Scripts mail-order and specialty pharmacy, it earns a dispensing margin each time it fills a prescription. It also collects premium revenue from health coverage sold in Asian and European markets, which arrives in local currencies.
What makes this company hard to replace?
An employer client that wants to move its medical and pharmacy coverage to separate vendors faces an implementation process that takes 12 to 18 months. Specialty pharmacy patients on high-cost biologics through Evernorth must go through complex prior authorization transfers and physician coordination before a new PBM can take over their care. Express Scripts mail-order patients face prescription transfer delays that typically force them to pay higher prices at a retail pharmacy in the meantime.
What limits this company?
Every time Cigna enters a new state market or adds a new employer client to its combined medical-pharmacy business, it must produce detailed paperwork proving that money moving between the Evernorth PBM side and the Express Scripts pharmacy side was priced fairly, as if the two were unrelated companies. State insurance departments require this documentation for every rebate dollar. That compliance work grows with every new market and every new client, and it cannot be automated away.
What does this company depend on?
Cigna cannot operate without Express Scripts mail-order pharmacy facilities to physically fill prescriptions, pharmaceutical manufacturer rebate contracts negotiated through Evernorth, state insurance licenses in every market where Cigna Healthcare sells coverage, claims processing systems that connect to Evernorth pharmacy networks, and Medicare Advantage and Medicaid managed care contracts in specific state markets.
Who depends on this company?
Employer groups that bought combined medical and pharmacy coverage through Cigna would face expensive plan redesigns and disruption for their employees if forced to find separate vendors. Patients with chronic conditions who use Express Scripts mail-order would face gaps in their therapy while prescriptions transfer to new pharmacies, requiring physician involvement. Specialty pharmacy patients receiving high-cost biologics through Evernorth would face prior authorization delays because a new PBM would have no record of their treatment history.
How does this company scale?
Negotiating drug rebates and adding pharmacy network contracts can cover millions more patients without a matching increase in administrative staff, so that part of the business grows cheaply. What does not scale easily is entering new state markets: each one requires local regulatory relationships, state-specific compliance infrastructure, and building out medical provider networks on the ground — none of which can be centralized or handled remotely.
What external forces can significantly affect this company?
The FTC is actively scrutinizing vertical arrangements between PBMs and pharmacies, and a ruling requiring structural separation would directly threaten the way Cigna makes money. CMS adjusts the benchmark rates it pays for Medicare Advantage plans, and those adjustments directly affect how profitable Cigna's government program business is in any given year. Cigna also sells health coverage in Asian and European markets, so swings in local currencies affect the value of that revenue when converted back to dollars.
Where is this company structurally vulnerable?
If the FTC required Cigna to sell either the Express Scripts pharmacy operations or the Evernorth PBM business, the link between deciding which drugs are covered and physically filling those prescriptions would be cut. The prior authorization records inside Evernorth would no longer have a captive pharmacy to route patients toward, and the ability to earn both an administrative fee and a dispensing margin on the same prescription would disappear entirely.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations align: return on equity is high relative to gross margin, revenue has grown for three consecutive years, and the company has been profitable for five years. Together they describe strong equity returns in a stable, growing context.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
How is this stock valued?
Three observations co-occur: the 14-week Choppiness Index is elevated (range-bound price), revenue increased year-over-year in each of the last three fiscal years, and the trailing OCF margin is elevated. The configuration describes a range-bound short-term price window alongside multi-year fundamental persistence.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph